All In Biotech

Drug Trial Radar · NCT05422612

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

800

Planned (sponsor's estimate)

Start

Nov 2, 2023

Primary completion

Jul 2028

Study completion Jul 2029

Sponsor

Lead sponsor
Global Coalition for Adaptive ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
U.S. Army Medical Research and Development Command; PPD Development, LP; Berry Consultants; Idorsia Pharmaceuticals Ltd.; Cambridge Cognition Ltd; Citeline
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the available cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). The master protocol describes the default procedures and analyses for all cohorts; treatment-specific eligibility requirements, safety and efficacy procedures, or endpoints are described in the cohort-specific appendices and reflected in the intervention-specific clinicaltrials.gov records.

Conditions

  • Post Traumatic Stress Disorder

Interventions

  • Intervention A Fluoxetine Hydrochloride (HCl)Drug

    Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.

  • Intervention A PlaceboDrug

    A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.

  • Intervention B Vilazodone Hydrochloride (HCl)Drug

    Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.

  • Intervention B PlaceboDrug

    A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.

  • Intervention C DaridorexantDrug

    Daridorexant will be administered 50 mg once daily.

  • Intervention C PlaceboDrug

    A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.

  • Intervention D SLS-002Drug

    • SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.

  • Intervention D PlaceboDrug

    A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit).Time frame: 12 Weeks
  2. Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.Time frame: 12 Weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Homestead Associates in Research, Inc.

    Miami, Florida

  • Advanced Discovery Research

    Atlanta, Georgia

  • Tripler Army Medical Center (TAMC)

    Tripler AMC, Hawaii

  • Cincinnati Veteran's Affairs Medical Center

    Fort Thomas, Kentucky

  • Walter Reed National Military Medical Center (WRNMC)

    Bethesda, Maryland

  • Upstate Clinical Research Associates, LLC

    Williamsville, New York

  • Wilford Hall Ambulatory Surgical Center (WHASC)

    San Antonio, Texas

  • Alexander T. Augusta Military Medical Center (ATAMMC):

    Fort Belvoir, Virginia

  • Madigan Army Medical Center

    Joint Base Lewis McChord, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.